Zinc Monotherapy as an Alternative Treatment Option for Decompensated Liver Disease due to Wilson Disease?

Background. Wilson disease is a rare metabolic disorder involving copper metabolism, and patients may present with a variable degree of hepatic, neurologic, and psychiatric manifestations. In the case of hepatic presentation, treatment is usually initiated with potentially toxic copper chelators (D-...

Full description

Saved in:
Bibliographic Details
Main Authors: Hansa Haftu, Mohammed Mustefa, Teklu Gebrehiwot
Format: Article
Language:English
Published: Wiley 2020-01-01
Series:Case Reports in Hepatology
Online Access:http://dx.doi.org/10.1155/2020/1275940
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1832553969672519680
author Hansa Haftu
Mohammed Mustefa
Teklu Gebrehiwot
author_facet Hansa Haftu
Mohammed Mustefa
Teklu Gebrehiwot
author_sort Hansa Haftu
collection DOAJ
description Background. Wilson disease is a rare metabolic disorder involving copper metabolism, and patients may present with a variable degree of hepatic, neurologic, and psychiatric manifestations. In the case of hepatic presentation, treatment is usually initiated with potentially toxic copper chelators (D-penicillamine or Trenton). Although zinc is of low toxicity and low cost for treatment of Wilson disease, it has been limited to the adjunctive as a single maintenance drug or for asymptomatic patients. The use of zinc monotherapy in patients suffering from a severe liver disease was not well studied. In our case report, we describe a pediatric patient who presented with liver failure and the use of zinc monotherapy in patients with severe hepatic manifestations. Case presentation. A 15-year-old male patient from Ethiopia presented with generalized body swelling (edema and ascites) with yellowish discoloration of his eyes and easy fatigability. He had hyperbilirubinemia, coagulopathy, hypoalbuminemia, and deranged liver enzymes. He had a Keyser–Fleischer ring visible with the naked eye, which was confirmed by slit-lamp examination. He had very low serum ceruloplasmin (<8 mg/L) and high 24-hour urine copper (150 mcg/dl). In accordance with the scoring system proposed by the 8th International Meeting on Wilson Disease and Menkes Disease, a diagnosis of Wilson disease was made. Zinc monotherapy with low copper diet was initiated for decompensated liver disease due to Wilson disease because of the inaccessibility of chelators (D-penicillamine or Trientine). After months of treatment with zinc, the patient experienced normalization of hepatic synthetic function and resolution of hypoalbuminemia and coagulopathy. The patient had also clinically stabilized (ascites, lower extremity swelling, edema, and jaundice were improved. Currently, the patient is on follow-up almost for the last four years in the gastrointestinal clinic. Conclusion. Our case shows that zinc has the potential for treatment in improving liver function. Though zinc has its own side effects, it is important and maybe an alternative treatment option in those with limited resources (not able to access chelators). This example hopefully will encourage future investigations and researches on zinc monotherapy for treating symptomatic decompensated hepatic Wilson disease.
format Article
id doaj-art-c42a5790f6f24a218d757fb715513e53
institution Kabale University
issn 2090-6587
2090-6595
language English
publishDate 2020-01-01
publisher Wiley
record_format Article
series Case Reports in Hepatology
spelling doaj-art-c42a5790f6f24a218d757fb715513e532025-02-03T05:52:44ZengWileyCase Reports in Hepatology2090-65872090-65952020-01-01202010.1155/2020/12759401275940Zinc Monotherapy as an Alternative Treatment Option for Decompensated Liver Disease due to Wilson Disease?Hansa Haftu0Mohammed Mustefa1Teklu Gebrehiwot2Mekelle University, College of Health Science, Pediatric and Child Health Department, Tigray, EthiopiaMekelle University, College of Health Science, Pediatric and Child Health Department, Tigray, EthiopiaMekelle University, College of Health Science, Clinical Pharmacist, Tigray, EthiopiaBackground. Wilson disease is a rare metabolic disorder involving copper metabolism, and patients may present with a variable degree of hepatic, neurologic, and psychiatric manifestations. In the case of hepatic presentation, treatment is usually initiated with potentially toxic copper chelators (D-penicillamine or Trenton). Although zinc is of low toxicity and low cost for treatment of Wilson disease, it has been limited to the adjunctive as a single maintenance drug or for asymptomatic patients. The use of zinc monotherapy in patients suffering from a severe liver disease was not well studied. In our case report, we describe a pediatric patient who presented with liver failure and the use of zinc monotherapy in patients with severe hepatic manifestations. Case presentation. A 15-year-old male patient from Ethiopia presented with generalized body swelling (edema and ascites) with yellowish discoloration of his eyes and easy fatigability. He had hyperbilirubinemia, coagulopathy, hypoalbuminemia, and deranged liver enzymes. He had a Keyser–Fleischer ring visible with the naked eye, which was confirmed by slit-lamp examination. He had very low serum ceruloplasmin (<8 mg/L) and high 24-hour urine copper (150 mcg/dl). In accordance with the scoring system proposed by the 8th International Meeting on Wilson Disease and Menkes Disease, a diagnosis of Wilson disease was made. Zinc monotherapy with low copper diet was initiated for decompensated liver disease due to Wilson disease because of the inaccessibility of chelators (D-penicillamine or Trientine). After months of treatment with zinc, the patient experienced normalization of hepatic synthetic function and resolution of hypoalbuminemia and coagulopathy. The patient had also clinically stabilized (ascites, lower extremity swelling, edema, and jaundice were improved. Currently, the patient is on follow-up almost for the last four years in the gastrointestinal clinic. Conclusion. Our case shows that zinc has the potential for treatment in improving liver function. Though zinc has its own side effects, it is important and maybe an alternative treatment option in those with limited resources (not able to access chelators). This example hopefully will encourage future investigations and researches on zinc monotherapy for treating symptomatic decompensated hepatic Wilson disease.http://dx.doi.org/10.1155/2020/1275940
spellingShingle Hansa Haftu
Mohammed Mustefa
Teklu Gebrehiwot
Zinc Monotherapy as an Alternative Treatment Option for Decompensated Liver Disease due to Wilson Disease?
Case Reports in Hepatology
title Zinc Monotherapy as an Alternative Treatment Option for Decompensated Liver Disease due to Wilson Disease?
title_full Zinc Monotherapy as an Alternative Treatment Option for Decompensated Liver Disease due to Wilson Disease?
title_fullStr Zinc Monotherapy as an Alternative Treatment Option for Decompensated Liver Disease due to Wilson Disease?
title_full_unstemmed Zinc Monotherapy as an Alternative Treatment Option for Decompensated Liver Disease due to Wilson Disease?
title_short Zinc Monotherapy as an Alternative Treatment Option for Decompensated Liver Disease due to Wilson Disease?
title_sort zinc monotherapy as an alternative treatment option for decompensated liver disease due to wilson disease
url http://dx.doi.org/10.1155/2020/1275940
work_keys_str_mv AT hansahaftu zincmonotherapyasanalternativetreatmentoptionfordecompensatedliverdiseaseduetowilsondisease
AT mohammedmustefa zincmonotherapyasanalternativetreatmentoptionfordecompensatedliverdiseaseduetowilsondisease
AT teklugebrehiwot zincmonotherapyasanalternativetreatmentoptionfordecompensatedliverdiseaseduetowilsondisease